Table 5 Cybersickness
Study | Cybersickness questionnaires | Cybersickness evaluation |
|---|---|---|
Kamm et al. 2023 [43] | No | n.r |
Heinrich et al. 2022 [30] | Simulator Sickness Questionnaire | No symptoms reported. SSQ results [mean (std)] = first intervention [2.36 (2.01)], second intervention = [2.45 (2.46)], third intervention [2.73 (2.34)] |
Park et al. 2021 [31] | No | Symptoms only in the first session, but the participant resolved in a few minutes |
Won et al. 2021 [39] | Simulator Sickness Questionnaire | 7 Participants reported no cybersickness, with 2 participants rating their cybersickness as “slight.” No participants quit any trial because of its effects SSQ results not reported |
Erhardsson et al. 2020 [32] | No | No serious adverse effects were observed during or after training. One participant felt slightly unsteady for a few hours post-training after the first sessions |
Marin-Pardo et al. 2020 [33] | Simulator Sickness Questionnaire | No symptoms reported SSQ results [mean (std)] = first session [5.56 (5.27)], last session: [6.35 (2.59)] |
Lee et al. 2020 [34] | No | No symptoms were reported in all patients |
Weber et al. 2019 [35] | Motion Sickness Susceptibility Questionnaire Short Form | No symptoms reported. MSSQ-Short indicating little to no cybersickness MSSQ-Short results [mean] = first session [1], last session [1.6] |
Vourvopoulos et al. 2019 [36] | No | n.r |
Osumi et al. 2019 [40] | No | n.r |
Huang et al. 2018 [37] | No | n.r |
Chau et al. 2017 [41] | No | n.r |
Osumi et al. 2017 [42] | No | n.r |